In this Urology Times educational supplement, we review the importance of understanding the CRPC–mCRPC transition in order to optimize standard screening procedures and identify patients with early metastatic disease who may benefit from therapeutic intervention.
Pembrolizumab/axitinib efficacy in ccRCC sustained at 5-year follow-up
June 6th 2023At a median follow-up of 67.2 months, the combination of pembrolizumab and axitinib continued to show an overall survival and progression-free survival benefit over sunitinib monotherapy in the first-line setting.
2 Clarke Drive
Cranbury, NJ 08512